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Intensive care is expensive, and thus a body of
research has focused on strategies to reduce its costs.
However, efforts to reduce the total cost of intensive
care have met with limited success, partly because of
the challenges of calculating how much a day in the
ICU actually costs. We discuss these challenges and
introduce the concept of total cost savings as an
outcome of critical care trials, assuming statistically
negative effects on mortality and quality of life.of course, bill for glucose strips. A tiny part of the hospital’sHealthcare is expensive, and intensive care is very
expensive. ICUs are estimated to consume up to one-third
of hospital costs and approximately 0.5 % of the US gross
domestic product [1]. It is therefore not surprising that a
lot of research has focused on strategies to reduce the cost
of intensive care. Many studies have calculated the ICU
cost by multiplying days in the ICU by cost per day, but
what is truly surprising is the complexity of calculating
the cost of a day in the ICU.
There are two common accounting formulas for
healthcare costing, conveniently termed top down and
bottom up. The top-down method takes the overall cost
of care for an ICU divided by the number of patient-days
of care delivered to calculate the average cost per day.
Similarly, the bill that a hospital sends to a payer for an
ICU day can be adjusted by some estimate of hospital
overheads to obtain an idea of the average cost for that
day. This method provides convenient numbers that are
used frequently in the literature. For example, the
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creativecommons.org/publicdomain/zero/1.0/used this approach to estimate that an ICU day cost
US$1,152 in 1999, or roughly three times the cost of a
hospital day [2]. In contrast, the bottom-up approach
requires very granular cost data. Every bandage, catheter,
lab test, and nursing and therapist hour must be accounted
for. Even with this level of detail, assigning a dollar figure to
these costs is challenging. A recent Time magazine article
infuriated readers by reporting that hospitals charged
US$18 for a glucose test strip that could be purchased at
Amazon for US$0.55 [3]. Unlike the Amazon shopper, the
hospital has to recoup the costs to order, store, track and,
bill to dispose of hazardous wastes must also be built into
the cost of glucose test strips. Of course, the hospital can
decide to charge US$0.55 for glucose test strips, as long as
it makes up these costs on aspirin or gauze. The rules for
bottom-up accounting are quite complicated, and it is not
clear how comparable these costs are between hospitals
that might use different methods. Even when bottom-up
data are available, the relative costs of an ICU day or a
hospital day are determined by the room and board billing
rate of the hospital [4]. Importantly, bottom-up and
top-down approaches give different cost estimates [5].
Clinicians, researchers and policy-makers have found
top-down numbers useful despite their limitations.
For example, if catheter-related bloodstream infections
extend the ICU length of stay by 4 days, then eliminating
each infection should save the healthcare system US$4,608
(4 ×US$1,152) in ICU costs. If a new sedative drug reduces
the ICU length of stay by 0.5 days and the ICU treats 300
patients, the ICU should see an additional US$172,800
(0.5 × 300 ×US$1,152) in the budget, minus the cost of the
drug. However, while these average ICU costs and
cost savings are easy to calculate and impressively large,
they are deeply misleading. In this article we discuss some
of the reasons why and explore the methods and rationale
for studying total cost savings as a surrogate endpoint in
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most hospital costs are fixed, rather than variable. A
detailed study of hospital costs at Cook County Hospital
in the United States found that the majority of the costs
were fixed and related to buildings, equipment, salaried
labor and overheads [6]. In addition, variable costs tend
to decrease as the length of stay increases; attempts to
reduce costs by reducing variable costs such as length of
stay or laboratory tests or medications have thus met
with limited success. For example, significant reductions
in hospital length of stay in the United States led to
eventual increases in healthcare costs because patient
care was simply shifted from hospitals to nursing homes
and other post-acute care services [7]. A study evaluating
reductions in length of stay in surgical patients similarly
found small financial opportunities by eliminating the
low-cost last days in the hospital [8]. The authors
concluded that a focus on utilization earlier in the
course of admission would yield greater cost savings.
There are three important reasons why reducing the
length of stay in the ICU may not necessarily lead to
overall cost savings. The first reason is that the variable
costs of the days or hours that are saved at the end of
the ICU stay are small compared with the first days [9].
In fact, the last days in the ICU have similar variable
costs to the first days on the ward [10]. An analysis that
assigns average costs to these inexpensive days therefore
grossly overestimates the potential savings for reductions
in length of stay. Second, depending on the reimbursement
strategy and perspective of the cost analysis, reducing the
ICU length of stay can paradoxically increase total ICU
costs, because the new patient replacing the one leaving
the ICU will require more intense and expensive care.
Increasing access to ICU beds for patients who require
them, and decreasing wait times in the emergency depart-
ment, ward or post-anesthetic care unit is clearly a positive
outcome, but it may not be a cost-saving one from the
ICU perspective. Finally, if an intervention reduces the
ICU length of stay by tacking on an equal or greater num-
ber of hospital days, the cost reduction will be significantly
less than that calculated by a focus on ICU average costs.
In a recent issue of Critical Care, Turunen and colleagues
explore the economic benefits of dexmedetomidine com-
pared with standard sedatives in reducing days of mechan-
ical ventilation [11]. The pharmaceutical company that
markets the drug performed this economic analysis, using
data from the Dexmedetomidine Versus Midazolam for
Continuous Sedation in the Intensive Care Unit (MIDEX)
and Dexmedetomidine Versus Propofol for Continuous
Sedation in the Intensive Care Unit (PRODEX) trials, to
measure cost savings attributable to dexmedetomidine.
Readers who were skeptical of the two trials published in
Journal of the American Medical Association because they
thought that midazolam was an inappropriate comparatorwill be equally skeptical of this analysis. Careful readers will
note that this study finds a statistically significant reduction
in ICU length of stay whereas the parent trials did not,
because it used different assumptions in counting the
length of stay for patients who died [12].
However, there are some strengths to Turunen and
colleagues’ study that can serve as a guide for future
investigations. First, the authors account for the fact that
different days in the ICU cost different amounts. They
used a hybrid of activity-based bottom-up cost accounting
to measure nursing activity using the Therapeutic
Intervention Scoring System to estimate, for example,
that a day on invasive mechanical ventilation cost 33 %
more than a day not ventilated. Second, several sensitivity
analyses were performed to see whether costing assump-
tions changed the results. Dexmedetomidine saved money
in all of the scenarios; but in some, particularly in
comparison with propofol, the savings are quite small
and must be considered against the increased rates of
bradycardia and hypotension.
The real question for intensivists to consider is posed
by the article’s claim that if dexmedetomidine reduces
the ICU length of stay by 30 h, then the same ICU staff
could care for 19 extra patients for every 100 patients
treated with the drug. If true, this important effect might
let you treat an additional 80 patients per year in a
typical 10-bed ICU. The problem with this conclusion is
that you could do it with the same staff. In most ICUs,
the last 30 h of an 8-day stay is provided by fewer
nurses, but in this example 80 of those last days will be
traded for new high-acuity first days of care. Unless the
ICU uses a fixed staffing ratio for patients regardless of
acuity, it is unlikely that the same staff could deliver this
additional care, because it is different care.
Critical care has struggled with meaningful surrogate
endpoints for trials [13]. Cost-minimization, the analysis
presented here, assumes that the considered treatments
have equivalent effects on patient-centered outcomes such
as mortality and quality of life. This strategy overcomes a
problem inherent in all nonmortality outcomes in critical
care, namely informative censoring from mortality [14].
For example, both early death and successful weaning
can reduce the duration of mechanical ventilation in a
weaning trial, but we routinely ignore this and focus on
duration of mechanical ventilation. Cost-minimization
analysis addresses the problem of differences in outcomes
by assuming they do not exist. This assumption has re-
sulted in cost-minimization analysis being largely replaced
by cost-effectiveness models that capture the uncertainty
in outcomes from statistically negative clinical trials rather
than ignoring them [15, 16].
Regardless of the technique, we believe that the research
question posed by this study is fundamental to critical
care. In the absence of compelling effects on mortality or
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outcome in critical care might be safe and significant
reductions in total cost. This outcome will capture
much of what we already look for in our surrogate
outcomes of duration of mechanical ventilation, organ
failure, rescue therapies and length of stay, and will
present them in a persuasive form to society and patients.
Critical care is a long way from adopting this outcome.
We need to develop understandable methods to express
the uncertainty in safety and outcomes, reliable techniques
to address informative censoring by death, and accurate
accounting that includes post-ICU costs, international
variations in labor and resource costs, and adequately
addresses the issue of declining variable costs over
time. Finally, and, most importantly, we need to see
whether these modeled cost savings result in efficiencies
that benefit our patients.
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